Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma
Mené sur 396 patients atteints d'un lymphome non hodgkinien indolent réfractaire au rituximab, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'obinutuzumab à un traitement par bendamustine
Since the advent of rituximab, a chimeric monoclonal antibody directed against CD20, there has been near universal integration of this drug into treatment regimens for B-cell non-Hodgkin lymphomas. In view of rituximab's ubiquitous implementation as either a single drug or in combination with chemotherapy, it was inevitable that a population of rituximab-refractory patients would emerge and pose a therapeutic dilemma for the oncologist. Rituximab refractoriness has been functionally defined, and accepted by the US FDA from a regulatory standpoint, as those instances in which a lymphoma either fails to respond to or progresses during any rituximab containing regimen, or progresses within 6 months of the last rituximab administration.
The Lancet Oncology , commentaire, 2015